2 days ago
6
, /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced its unaudited financial results for the six months ended September 30, 2024.
Financial Highlights for the Six Months Ended September 30, 2024:
- Net Revenues: The Company reported net revenues of $11,091,189, an increase of 58.9% compared to $7,009,209 for the same period in 2023.
- Revenue Breakdown:
| Six Months ended
Get the latest news
Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy. September 30, 2024 |
| Six Months ended
September 30, 2023 | ||||||
| Supply chain services | $ | 6,329,678 | $ | 4,646,951 | ||||
| Procurement and distribution | 4,759,301 | 2,346,931 | ||||||
| Consignment sales and other revenue | 2,210 | 15,327 | ||||||
| Total Revenue | $ | 11,091,189 | $ | 7,009,209 | ||||
- Supply Chain Services: $6,329,678, up 36.3% from $4,646,951 for the same period in 2023.
- Procurement and Distribution: $4,759,301, a 102.7% increase from $2,346,931 for the same period in 2023.
- Consignment Sales and Other Revenue: $2,210, down from $15,327 for the same period in 2023.
- Gross Profit: The gross profit for the period was $1,905,603, a 42.6% increase from $1,335,988 for the same period in 2023.
Total Expenses
- Total Expenses: Increased to $10,066,706 for the six months ended September 30, 2024, up from $6,667,999 for the same period last year.
| Six Months ended September 30, 2024 | Six Months ended September 30, 2023 | |||||||
| Changes in inventories of merchandised goods | $ | 4,513,873 | $ | 2,171,361 | ||||
| Storage cost | 530,012 | 463,412 | ||||||
| Transportation cost | 2,619,599 | 1,046,455 | ||||||
| Consumption of packing material | 514,714 | 515,594 | ||||||
| Depreciation and amortization | 30,153 | 31,727 | ||||||
| Labor cost | 1,318,041 | 1,589,164 | ||||||
| Outsourcing expenses | 328,755 | 202,169 | ||||||
| Others | 211,559 | 648,117 | ||||||
| Total cost of sales, selling, general and administrative expenses | $ | 10,066,706 | $ | 6,667,999 | ||||
Net Income
- Net Income: The Company achieved a net income of $828,559, a 232.6% increase compared to $249,037 in the same period last year.
Management Commentary
Lap Sun Wong, Chief Executive Officer of HKPD, stated, "The Company has delivered a strong performance for the six months ended September 30, 2024, demonstrating our ability to grow in a competitive and evolving market. The significant increase in net revenues reflects the effectiveness of our strategic initiatives to enhance our supply chain and procurement services. Despite the rise in expenses due to increased marketing efforts and workforce expansion, our net income reflects our focus on profitability and operational efficiency."
Man Bun Kwok, Chief Financial Officer, added, "While we are pleased with our financial progress, we remain mindful of the importance of maintaining a disciplined cost structure as we scale operations. Our investment in marketing aims to capture additional market share in the OTC pharmaceutical supply chain sector, and we believe these efforts will continue to drive growth in the coming periods."
About Hong Kong Pharma Digital Technology Holdings Limited
Hong Kong Pharma Digital Technology Holdings Limited offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited ("Joint Cross Border"), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.
Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China.
Joint Cross Border's comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers.
For more information, please visit the Company's website: www.9zt.hk.
Forward-Looking Statements
All forward-looking statements, expressed or implied, in this release are based only on information currently available to us and speak only as of the date on which they are made. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this release. Except as otherwise required by applicable law, we disclaim any duty to publicly update any forward-looking statement to reflect events or circumstances after the date of this release. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in our filings with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov.
For investor and media inquiries please contact:
Hong Kong Pharma Digital Technology Holdings Limited
Media Contact: [email protected]
Investor Relations: [email protected]
Telephone: +852 2618-9289
HONG KONG PHARMA DIGITAL TECHNOLOGY HOLDINGS LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
(Expressed in U.S. dollar, except for the number of shares)
| For the Six Months Ended September 30, | ||||||||||||
| Note | 2024 unaudited | 2023 unaudited | ||||||||||
| Revenues | 7 | $ | 11,091,189 | $ | 7,009,209 | |||||||
| Cost of revenues | 8 | (9,185,586) | (5,673,221) | |||||||||
| Gross profit | 1,905,603 | 1,335,988 | ||||||||||
| Other income | 9 | 804 | 427 | |||||||||
| Operating expenses: | ||||||||||||
| Selling, general and administrative expenses | 8 | (881,120) | (994,778) | |||||||||
| Other gains/(losses), net | 10 | 1,751 | (32,817) | |||||||||
| Total operating expenses | (879,369) | (1,027,595) | ||||||||||
| Operating profit | 1,027,038 | 308,820 | ||||||||||
| Financial income | 11 | 1,078 | 156 | |||||||||
| Finance costs | 11 | (49,254) | (34,812) | |||||||||
| Finance costs, net | (48,176) | (34,656) | ||||||||||
| Profit before income taxes | 978,862 | 274,164 | ||||||||||
| Income tax expense | 12 | (150,303) | (25,127) | |||||||||
| Net profit for the year | 13 | 828,559 | 249,037 | |||||||||
| Less: profit attributable to non-controlling interests | - | - | ||||||||||
| Profit attributable to owners of the Company | 828,559 | 249,037 | ||||||||||
| Other comprehensive income | ||||||||||||
| Foreign currency translation adjustments | 20,032 | 227 | ||||||||||
| Comprehensive income attributable to the Company's shareholders | $ | 848,591 | $ | 249,264 | ||||||||
| Earnings per share | ||||||||||||
| Basic and diluted * | 15 | $ | 0.083 | $ | 0.036 | |||||||
| Weighted average number of shares outstanding | ||||||||||||
| Basic and diluted * | 10,000,000 | 6,843,000 | ||||||||||
HONG KONG PHARMA DIGITAL TECHNOLOGY HOLDINGS LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Expressed in U.S. dollar, except for the number of shares)
| September | March 31, | |||||||||
| Note | 30, 2024 unaudited | 2024 audited | ||||||||
| ASSETS | ||||||||||
| NON-CURRENT ASSETS: | ||||||||||
| Property and equipment, net | 16 | 119,407 | 103,242 | |||||||
| Intangible assets, net | 17 | 89,299 | 31,825 | |||||||
| Right of use assets, net | 25 | 1,073,857 | 730,451 | |||||||
| TOTAL NON-CURRENT ASSETS | 1,282,563 | 865,518 | ||||||||
| CURRENT ASSETS: | ||||||||||
| Deferred IPO costs | 21 | 2,161,496 | 1,260,075 | |||||||
| Inventories | 18 | 555,522 | 933,299 | |||||||
| Trade receivables, net | 19 | 4,880,309 | 3,698,757 | |||||||
| Other receivables and prepayments | 19 | 902,406 | 1,262,351 | |||||||
| Amount due from related parties | 23 | 14,755 | 19,971 | |||||||
| Restricted cash | 401 | 7,682 | ||||||||
| Cash and cash equivalents | 20 | 364,990 | 619,575 | |||||||
| TOTAL CURRENT ASSETS | 8,879,879 | 7,801,710 | ||||||||
| TOTAL ASSETS | $ | 10,162,442 | $ | 8,667,228 | ||||||
